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Abstract: This study deals with the preparation and investigation of a nanoscale delivery system 
for the anticancer drug doxorubicin (DOX) using its complexation with polyanionic carbohy-
drate dextran sulfate (DS). Dynamic light scattering, SEM, and zeta potential determination 
were used to characterize nanocomplexes. DOX-DS complexation was studied in the presence 
of ethanol as a hydrogen-bond disrupting agent, NaCl as an electrostatic shielding agent, and 
chitosan as a positively charged polymer. Thermodynamics of DOX-DS interaction was studied 
using isothermal titration calorimetry (ITC). A dialysis method was applied to investigate the 
release profile of DOX from DOX-DS nanocomplexes. Spherical and smooth-surfaced DOX-DS 
nanocomplexes (250–500 nm) with negative zeta potential were formed at a DS/DOX (w/w) 
ratio of 0.4–0.6, with over 90% drug encapsulation efficiency. DOX when complexed with DS 
showed lower fluorescence emission and 480 nm absorbance plus a 15 nm bathometric shift in 
its visible absorbance spectrum. Electrostatic hydrogen bonding and π-π stacking interactions 
are the main contributing interactions in DOX-DS complexation. Thermal analysis of DOX-DS 
complexation by ITC revealed that each DOX molecule binds with 3 DS glycosyl monomers. 
Drug release profile of nanocomplexes showed a fast DOX release followed by a slow sustained 
release, leading to release of 32% of entrapped DOX within 15 days. DOX-DS nanocomplexes 
may serve as a drug delivery system with efficient drug encapsulation and also may be taken 
into consideration in designing DOX controlled-release systems.
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Introduction
The anthracycline antibiotic doxorubicin (DOX) is a potent chemotherapeutic agent 
that has been used for over 30 years to treat a wide spectrum of human malignan-
cies, especially breast cancer and lymphoma.1 However, despite its efficiency and 
wide use, its therapeutic utility is limited due to dose-limiting toxicities such as bone 
marrow suppression2 and congestive heart failure.3–5 Another challenge met by DOX 
is the development of resistance mechanisms by tumor cells,6–8 which reduce the 
intracellular drug concentration either by reducing drug uptake or enhancing drug   
efflux.9
Numerous studies have sought the solution to these problems in nanoparticulate 
carriers.10–19 Nanoscale drug carriers are intended to overcome drug resistance presum-
ably by means of being enveloped in an endosome when entering the cell and thereby 
bypassing P-glycoprotein efflux pumps (one of the main drug-resistance mechanisms) 
and preventing drug efflux from the resistant tumors.20–23 One of the nano-oriented 
approaches undertaken to this end is the complexation of drugs with polymers.16 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Electrostatic interaction can result in complexation between 
cationic drugs and anionic polymers.24,25 DOX possesses 
positive charge and has been studied for its complexation 
with various anionic polymers such as poly(acrylic acid),26,27 
γ-polyglutamic acid,28 polyaspartate,24,29 polyglutamate,30 
block ionomers of aspartate, benzyl aspartate,31–34 benzyl 
glutamate,29 and polyethylene oxide. These polyanions form 
polyelectrolyte complexes with DOX. Aromatic stacking and 
hydrogen bonding interactions are also assumed to play an 
important role in such complexes.26,27
Dextran sulfate (DS) is a highly anionic carbohydrate 
which has been investigated for improving encapsulation 
efficiency of DOX. Successful augmentation of DOX 
encapsulation into albumin microspheres was achieved with 
the aid of DS.35 Janes et al employed DS to increase DOX 
loading into chitosan nanoparticles.36 DOX has also been 
encapsulated into chitosan microparticles formulated via the 
complex coacervation method with DS.37 In a series of stud-
ies, DOX was conjugated with polymeric dextrans of various 
molecular weights and it was found that the cytotoxicity, 
and the DNA-binding kinetics of DOX were subsequently 
modified.38–40 Antitumor activity, acute toxicity, and plasma 
pharmacokinetics of DOX-DS conjugate were compared 
with free DOX in rats following iv administration. Lam 
et al41,42 showed that the DOX-DS conjugate exerted superior 
antitumor activity to the free DOX in multidrug-resistant cell 
lines, the reason being cited as a decrease in the removal 
rate of DOX from P-glycoprotein overexpressing multidrug-
resistant cells once conjugated to dextran. Another group 
further investigated this possibility of overcoming the DOX 
resistance in vitro by using DOX-DS conjugate in a multi-
drug resistance subline of human carcinoma and found simi-
lar results.43 Herein, we report the formation of electrostatic 
complexes at nanoscale between positively charged DOX 
and negatively charged DS (DOX-DS). The experimental 
approach includes probing the nature of interactions in 
DOX-DS complexation, characterization of DOX-DS nano-
complexes, and release profile of drug   molecules. DOX-DS 
interaction is also studied in the presence of the positively 
charged polymer chitosan.
Materials and methods
Materials
DS (D4911, MW of 8000) was obtained from Sigma 
Chemical Co. Doxorubicin (purity ∼98.5%) was purchased 
from RPG Life Sciences Limited (Ankleshwar, India). All 
other chemicals were of analytical grade;   deionized water 
was used throughout.
Preparation and characterization  
of DOX-Ds nanocomplexes
DOX HCl was dissolved in deionized water at a concen-
tration of 0.1 mg/mL. To this solution, an equal volume 
of DS solution in deionized water was added to give final 
DOX-DS solutions of 0.1, 0.2, 0.3 0.4, 0.5, 0.6, 0.8, 1, 1.5, 
2, 3, and 4 w/w. Solutions were left for 45 minutes in the 
dark while stirring. The hydrodynamic mean diameter and 
zeta potential of DOX-DS nanocomplexes were measured 
by, respectively, dynamic light scattering and laser doppler 
electrophoresis using Zetasizer (Nano-ZS, Malvern, UK). All 
dynamic light scattering measurements were performed with 
a wavelength of 633 nm at 25°C with an angle detection of 
90°. All   measurements were run in triplicate.
Analysis of encapsulation efficiency
Encapsulation efficiency of DOX-DS nanocomplexes was 
analyzed by ultracentrifugation of complexes at 80,000 rpm for 
30 minutes. To make sure that free drug did not precipitate at 
that high rotation speed, free drug solution was used as control. 
The concentration of remaining DOX in supernatant was mea-
sured spectroscopically at 480 nm and encapsulation efficiency 
was determined by applying the following equation:
Encapsulation
efficiency
totals upernatant
(%)
[] []
[
=
− DOX DOX
DOX] ]total
×100
scanning electron microscopy (seM)
The morphological characteristics of nanoparticles were 
observed by using an SEM (XL 30, Philips, The Netherlands). 
Nanoparticle suspensions were spread on an aluminium disc 
and allowed to dry at room temperature. The dried nanopar-
ticles were then coated with gold metal using a sputter coater 
(SCD 005, Bal-Tec, Switzerland).
Spectrophotometry and fluorescence 
spectroscopic study of DOX-Ds 
nanocomplexes
DOX solutions of different concentrations were mixed with 
DS in ratios of 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 
0.8:1, 1:1, 1.5:1, 2:1, 3:1, and 4:1. The absorbance of the 
resulting nanocomplexes was measured at 480 nm using a 
UV-VIS spectrophotometer (Scinco S-3100, Korea). The 
fluorescence measurement was carried out on a fluores-
cence spectrophotometer (Cary Eclipse, Varian, Australia) 
equipped with a thermostatically controlled cell holder at an 
ambient temperature. The monochromatic slits were set at International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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5 nm to reduce the intensity of the signal depending on the 
experiment. The wavelength of excitation was 470 nm and 
the spectra were recorded between 500 and 700 nm. Water 
was used as the baseline reference in both studies.
DOX-Ds interaction study
To come to a deeper understanding of the nature of inter-
actions involved, DOX-DS complexation was studied in 
presence of ethanol as a hydrogen-bond disrupting agent 
and NaCl as an electrostatic shielding agent. Ethanol 
was added to the DOX-DS nanocomplex solution (DOX: 
51.7 µM, DS/DOX: 0.6) at different v/v proportions and the 
absorbance at 480 nm was measured and compared with that 
of pure DOX in the corresponding ethanol–water cosolvent 
system. The absorbance of the DOX-DS formulation was also 
studied in different ionic strengths, ie, different concentra-
tions of NaCl.
In addition, the absorbance of the DOX-DS system was 
examined in presence of chitosan (CS) as a positively charged 
polymer. CS was added to DOX-DS system (DOX: 51.7 µM, 
DS/DOX: 0.6) at CS/DS (w/w) ratio of 0.25, 0.5, 0.75, 1, 2, 
and 3; the resulting 480 nm absorbance was studied.
In vitro evaluation of DOX release  
from nanocomplexes
In vitro drug release profile of DOX-DS nanocomplexes was 
investigated as follows. Nanocomplex suspension (DOX 
50 µg/mL, DS/DOX 0.6) was placed into dialysis tubing 
(Sigma dialyses tubes Mw cutoff 12 kDa) with phosphate 
buffer solution (PBS) as release medium. The nanocomplex 
was then incubated in a shaking water bath at 37°C. At 
appropriate time intervals, a certain volume of the release 
medium was taken out and was replaced by the same volume 
of fresh PBS. Sampling volumes were selected to ensure sink 
conditions, ie, to maintain the drug concentration in dialysate 
below 10% of its aqueous solubility. The amount of DOX in 
the release medium was examined by HPLC. A solution of 
free DOX was also loaded into dialysis tubing and dialyzed 
under the same condition as control.
The cumulative fraction of released DOX was calculated 
according to the following equation:
Cumulative released DOX% (tn)
=×
totalreleasedDOX
initialDOXinnanocomplexformulation
100
 
=× ∑ [DOX]V+[DOX]V
[DOX]V
ii ff i=1
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00
100
 
where [DOX]i and Vi represent the measured DOX   concentration 
in and volume of sample taken at time ti; [DOX]f and Vf, final 
measured DOX concentration in and final volume of release 
medium at time (tn); [DOX]0 and V0, initial DOX concentration 
in and volume of the nanocomplex formulation under study.
In addition, DOX release rate (%/hr) was estimated as:
releaserate
d(%DOX)
dt
(%DOX) (%DOX)
tt
tt
nn -1
nn 1 ==
−
−
−
where (%DOX)tn and (%DOX)tn−1 are percentage of released 
DOX at sampling time tn(hr) and tn−1(hr).
hPLc analysis of DOX
Released DOX in the dialysate was quantified by C18 reverse 
phase column connected to a Knauer HPLC system; the 
Knauer HPLC apparatus consisted of an S 1000 pump with 
fluorescence detector (RF 10 Axl). Mobile phase was com-
posed of a mixture of 0.01 M potassium dihydrogen phos-
phate and acetonitrile in a ratio of 65:35 whose final pH was 
adjusted to 4.2 using phosphoric acid. The flow rate was set to 
1 mL/minute and the fluorescence (excitation 470 nm, emission 
550 nm) was recorded. All determinations were carried out at 
ambient temperature. Under these conditions DOX showed a 
retention time of about 4 minutes. DOX concentrations were 
calculated with reference to a calibration curve.
ITc study
The isothermal titration microcalorimetric experiments were 
performed with ITC instrument (VP-ITC, MicroCal, LLC, 
Northampton, MA). The titration vessel was made from 
stainless steel. DS solution (4797 µM glycosyl unit) was 
injected by use of a Hamilton syringe into the calorimetric 
titration vessel, which contained 1.8 mL DOX (862 µM). 
Thin (0.15 mm inner diameter) stainless steel hypodermic 
needles, permanently fixed to the syringe, reached directly 
into the calorimetric vessel. Injection of the DS solution into 
the perfusion vessel was repeated 20 times, with 10 µL per 
injection. The calorimetric signal was measured by a digital 
voltmeter which was part of a computerized recording sys-
tem. The heat of each injection was calculated by the Origin 
7.0 software program (OriginLab Corp, Northampton, MA). 
The microcalorimeter was frequently calibrated electrically 
during the course of the study.
The ITC of study was also performed with DOX and DS 
solved in 0.15 M aqueous solution of NaCl (ionic strength 
0.15 M). Injections were carried out 20 times (15 µL each 
time).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Results
characterization of nanocomplexes
As illustrated in Table 1, mean hydrodynamic diameter, poly-
dispersity index, and zeta potential of DOX-DS nanocom-
plexes containing DOX at the concentration of 0.05 mg/mL 
and different DS/DOX ratios were measured. Among dif-
ferent DS/DOX ratios examined, ratios between 0.4 and 0.6 
led to nanocomplexes.
Complexation efficiency
The efficiency of DOX encapsulation by DOX-DS nano-
complexes was highly affected by DS/DOX ratio. DOX 
complexation was enhanced with increasing DS/DOX ratio 
until it reached a peak of 95% at a DS/DOX ratio of 0.5. 
Efficiency then declined with further increments in the 
DS/DOX ratio (Figure 1).
surface morphology of nanocomplexes
Figure 2A clearly shows regular smooth and spherical nano-
complexes free from aggregation.
Absorbance and florescence spectrum  
of DOX-Ds nanocomplexes
Absorbance spectrum of DOX in water shows a maximum at 
480 nm and 2 shoulders at 500 and 535 nm. Complexation 
with DS as depicted in Figure 2B caused a bathochromic shift 
to λmax 495 nm, and a hypochromic and broadened spectrum. 
No shift was observed in the florescence emission spectrum, 
but the intensity was lowered more drastically compared with 
the visible absorbance spectrum (Figure 2C).
The relative decrease in 480 nm absorbance of DOX-DS 
complexes with respect to free DOX was independent of DOX 
concentration and dependent on DS/DOX ratios. As shown 
in Figure 3, absorbance decreased with further addition of 
DS until a plateau (/.) AA
DOX DS DOX
480 480 06 8
− =  was achieved at 
DS/DOX ratio of 0.4, after which no further decrease in the 
above absorbance fraction was observed.
DOX-Ds interaction
To investigate the role played by hydrogen bond and 
  electrostatic interaction in DOX-DS complexation, such 
interactions between DOX and DS were inhibited by 
the addition of ethanol and NaCl and the corresponding 
absorbance was measured. The results revealed that in pres-
ence of either agent, the absorbance increased; moreover, 
at concentrations 50% v/v ethanol or 0.3 M NaCl, the 
absorbance of DOX cosolved with DS was equal to that of   
free drug (Figures 4A and 4B).
Moreover, polycationic carbohydrate was demonstrated 
to influence DOX-DS interaction as well. Figure 4C shows 
that the presence of CS up to CS/DS (w/w) 0.5 caused a slight 
decrease in DOX-DS absorbance. Higher CS/DS (w/w), 
however, increased DOX-DS absorbance, until at CS/DS 
(w/w) 3, DOX-DS absorbance reached that of free drug.
In vitro drug-release studies
A dialysis method was applied to investigate the release 
profile of DOX from DOX-DS nanocomplexes. Figure 5A 
shows that 14% of DOX was released during the first 
24 hours followed by slow release of 32% over a time span 
of 15 days. Figure 5B presents a clearer view of release 
behavior of DOX-DS nanocomplexes. Furthermore, a 
controlled release study of free DOX revealed complete dif-
fusion of drug through dialysis membrane within 10 hours 
(Figure 5C).
Thermal analysis of DOX-Ds 
complexation
The thermodynamics of DOX-DS interaction was studied by ITC. 
Analysis by Thermometric Digitam 3 (Figure 6) yielded a binding 
constant of 0.337 ± 0.00139 molDOX/molGlycosyl, an enthalpy value 
(∆H) of value of −6.989 kcal/mol, and an entropy value (∆S) 
of 0.011 kcal/mol°K. Free energy (∆G) was calculated equal 
to −10.267 kcal/mol by putting ∆H and ∆S into the Gibbs free 
energy equation (∆G = ∆H − T∆S) (Figure 6A).
Table 1 Mean hydrodynamic diameter, polydispersity index (PDI), 
and zeta potential of DOX-Ds complexes containing DOX at the 
concentration of 0.05 mg/mL and different Ds/DOX ratios
DS/DOX  
ratio (w/w)
Mean hydrodynamic  
diameter (nm)
PDI Zeta  
potential (mV)
4:10 461 ± 31 0.257 ± 0.061 −19.5 ± 1.4
6:10 279 ± 28 0.29 ± 0.014 −33.2 ± 3.3
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For DOX-DS interaction in the presence of NaCl 0.15 M, the 
thermodynamic parameters obtained were: ∆H = −5.37 kcal/mol; 
∆S = 0.006 kcal/mol; ∆G = −7.158 kcal/mol (Figure 6B); bind-
ing constant was 0.757 ± 0.0061 molDOX/molGlycosyl.
Discussion
The main objective of this study was to study DOX-DS 
complexation as a potential drug carrier. DOX (Figure 7) is 
composed of an aglycone moiety to which an amino sugar 
daunosamine is attached via a glycosidic bond. The aglycone 
part is a tetracyclic chromophore adiamycinone in which the 
B, C, and D rings form a planar anthraquinone system. These 
aromatic rings result in π-π stacking properties of DOX, which 
allows its intercalation into the DNA double helix (one of the 
mechanisms of action proposed for this anticancer drug). In 
addition, the amino sugar of DOX has a pKa value of 8.6, which 
confers alkaline properties onto this molecule and positive charge 
at neutral pH.44,45 Because of the positive charge of DOX, DOX 
is expected to associate at a high level with polyanionic DS.
The importance of electrostatic interaction in DOX-DS 
complexation was established by studying the absorption 
spectrum under different ionic strengths, ie, different concen-
trations of NaCl. Na+ and Cl− shield electrostatic charge of 
DS and DOX, respectively, and hamper their interaction with 
one another. At ionic strengths 0.3 M, DOX-DS electro-
static interaction is thoroughly disturbed and the absorption 
spectrum is not different from that of free DOX. The result 
is in accordance with that of Kitaeva et al who observed 
preservation of florescence spectrum of DOX when binding 
with polyacrylic acid in the presence of NaCl.26 On the other 
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Figure 2 A) scanning electron micrographs of doxorubicin–dextran sulfate (DOX-Ds) nanocomplexes (DOX: 60 µg/mL, Ds/DOX [w/w]: 0.6), B) UV-visible spectrum of 
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hand, despite the weakening effect of NaCl on complexation 
of DOX with pluronic P85-b-polyacrylic acid block copoly-
mers, Tian et al reported no significant dissociation of DOX-
pluronic P85-b-poly(acrylic acid) block copolymers.28 ITC 
experiments also demonstrated DOX-DS interaction to be 
strongly salt-dependent; the enthalpy of binding decreased 
from ∼−7.489 to ∼−5.37 kcal/mol in the presence of NaCl 
0.15 M. The binding constant also increased from 0.33 to 
0.75 molGlycosyl/molDOX; the shielding effect of NaCl weakens 
the intrarepulsion of the negatively charged sulfate groups 
and makes the DS structure less extended. As a result, higher 
numbers of glycosyl units can be accommodated around each 
DOX molecule leading to a higher molGlycosyl/molDOX ratio.
Furthermore, addition of an H-bond disturbing agent such 
as ethanol to the system caused recovery of the DOX absorp-
tion spectrum. This indicates the contribution of hydrogen 
bonds to DOX-DX nanocomplexes. According to Tian et al, 
these hydrogen bonds are ascribed to substituent (HO-C-CO-
CH2OH) shown by a dashed circle in Figure 7,27,46 which also 
takes part in its interaction with DNA.47
Addition of DS to DOX resulted in a decrease in the opti-
cal density of DOX solution (λmax = 480 nm) along with a 
bathochromic shift of about 15 nm. Such alteration in DOX 
spectra was previously reported in the interaction of DOX 
with other anionic biopolymers such as DNA,48 polyacrylic 
acid,26 and γ-polyglutamic acid.28 Florescence intensity of 
DOX was also weakened by DS complexation. However, 
the reduction in florescence was greater than the reduction 
in 480 nm absorbance.
In addition, there is a threshold for this hypochromic 
effect of DS. In fact, complexation of DOX with DS reduces 
its absorbance to 0.68 with respect to free drug at a DS/DOX 
ratio of 0.4; above this ratio, further addition of DS does not 
affect absorbance of DOX.
On the other hand, the complexation efficiency curve 
obtained by the ultracentrifugation method shows a peak 
rather than a plateau; the curve indicates a maximum associa-
tion of DOX with DS at a DS/DOX ratio of 0.5. The results 
reveal that DOX is encapsulated in up to 95% of DOX-DS 
complexes up to 0.5 and then declines again at higher DS/DOX 
ratios. Margaritis et al also reported such high DOX compl-
exation efficiency in DOX-γ-polyglutamic acid complexes.28 
This discrepancy between spectroscopy and encapsulation 
studies may be resolved through dynamic light scattering 
measurements according to which DOX-DS   complexes form 
particles at a nanoscale level at DS/DOX ratios of 0.4 to 0.6. 
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From all these results, the following mechanism is suggested 
for DOX-DS complexation: negatively charged DS interacts 
electrostatically with positively charged DOX molecules, 
and this interaction is strengthened by hydrogen-bonding 
interactions between hydroxyl groups of carbohydrate DS 
and hydroxyl groups attached to the anthraquinone ring in 
DOX. These interactions bring aromatic-structured DOX 
molecules in each other’s   vicinity and facilitate π-π stacking 
interactions between them. In fact, DOX molecules are known 
to form self-associated structures at [DOX] 130 µM;49 this 
gives rise to a change in the absorption spectrum of DOX, a 
phenomenon known as metachromasy.50 In the presence of a 
polyanionic chain such as DS, this metachromatic behavior 
occurs at lower DOX concentrations.
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As DS/DOX ratios increase up to 0.4, more DOX molecules 
become involved in electrostatic and hydrogen-bonding inter-
actions with DS chains and stacking interactions with each 
other, and consequently DOX absorbance decreases. At a 
DS/DOX ratio of 0.4, DOX comes into equilibrium between 
bulk solution and DOX-DS complexes; DS ratio is high enough 
to accommodate a maximum fraction of DOX. As illustrated 
in Figure 8, in the 0.4–0.6 range, a stacked array of DOX 
molecules acts as a physical crosslinker which, along with 
DOX-DS electrostatic interaction, makes DOX-DS complexes 
compact enough to form drug–polymer nanocomplexes. With 
further addition of DS to the system at DS/DOX  0.6, DOX 
molecules are distributed among a higher number of DS chains 
and are positioned farther from each other; stacking interac-
tions are weakened and the DOX-DS network is loosened. 
Therefore, DOX-DS complexes are not compact enough to 
form nanocomplexes and are of insufficient density to sediment 
during ultracentrifugation, which explains the descending part 
of the encapsulation curve. In fact, a close look at the absorp-
tion spectrum of the supernatant of ultracentrifuged DOX-DS 
complexes reveals the bathometric shift in DOX spectrum 
at DS/DOX  0.6; this confirms the presence of DOX-DS 
complexes not sedimenting by ultracentrifugation.
Thermal analysis of DOX-DS complexation by ITC 
revealed a binding constant of 0.337 ± 0.00139 mol DOX 
unit per 1 mol DS glycosyl unit; in other words, each DOX 
molecule binds with 3 DS glycosyl monomers. The ITC curve 
shows a jump in ∆H of system from DOX/glycosyl unit molar 
ratio 0.25–0.4, equal to 0.18–0.3 DS/DOX (w/w). It seems 
that a DS/DOX ratio of 0.18 is a critical point where electro-
static interaction is enough to stimulate DOX-DS binding via 
H-bonding and then stacking interactions, and consequently 
results in the onset of the exothermic peak.
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According to the in vitro release study, DOX-DS 
nanocomplexes release 14% of DOX at a fast rate during the 
first 24 hours. This is probably due to release of DOX mol-
ecules weakly bound with DS. However, the remaining DOX 
molecules are tightly complexed to DS by several electrostatic 
hydrogen-bonding or π-π interactions; 32% of this strongly 
entrapped DOX is released slowly within 2 weeks. Controlled 
release study of free DOX also demonstrated fast diffusion of 
drug into dialysate under sink conditions, which proves that 
diffusion through dialysis tubing (MWCO 12 kDa) is not a bar-
rier to the passing of the drug, freed from nanocomplexes, into 
dialysate. Such DOX-DS nanocomplexes may be employed in 
designing systems for controlled release of DOX. However, in 
systems dealing with ionic polymers, eg, CS nanoparticles,36,37 
the competitive effect of the second ionic polymer on DOX-DS 
interaction should be borne in mind. Contrary to Janes et al,36 
who observed only partial dissociation of DOX-DS complex in 
DS/DOX (w/w) 10, our results showed complete resumption of 
DOX absorbance at CS/DOX (w/w)  3, indicating complete 
dissociation of DOX-DS complexation. The higher charge 
density of CS and its lower steric hindrance compared with 
bulky DOX molecules makes it a more favorable electrostatic 
partner for DS and disrupts DOX-DS complexation.
Conclusion
DOX-DS nanocomplexes may serve as a drug delivery 
system with efficient drug encapsulation. Complexes are in 
the nanoscale range at a DS/DOX (w/w) ratio of 0.4–0.6. 
Electrostatic hydrogen bonding and aromatic interactions 
play the main roles in their formation. The DOX release pro-
file of nanocomplexes shows an initial fast release followed 
by a sustained release. DOX-DS interaction is affected by 
other anionic polymers, an important point when applying DS 
in order to enhance DOX encapsulation into other polymeric 
delivery systems.
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